Answer
Lanadelumab inhibits active plasma kallikrein, reducing the generation of bradykinin associated with inflammation and swelling in hereditary angioedema attacks.
Sources for this answer
- TAKHZYRO 300 mg solution for injection in pre-filled syringeTakeda UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 8Document updated
Sources checked